Skip to main content
. 2017 Aug 17;9(2):1602–1616. doi: 10.18632/oncotarget.20308

Figure 1. Gemcitabine (GCB) reduces cell viability in human osteosarcoma cells.

Figure 1

LM7, CCH-OS-D, and K7M3 cells were treated with GCB as indicated in figure for 24, 48, and 72 hours. Cell viability was determined by Trypan blue exclusion assay. Means ± standard deviation of three independent experiments are shown. *p < 0.05 compared with control.